JPM

With needed funds in its pocket, Biocon is prepared to simplify and integrate its growing off-patent medicines portfolio under one roof.

Execs at Biotech Showcase debated business models and platform monetization strategies for AI drug discovery companies, with some arguing they should develop internal pipelines and others advocating for partnership models.

Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.

Amneal sees vertical integration of its biosimilars business, as well as global partnerships, as a key advantage to remain at the top of the game ahead of upcoming competition.

After years of restructuring and remediation, Viatris says its base business has stabilized and it now expects cost savings, new launches and business development to drive renewed growth beginning in 2026.

Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.

In a presentation at the J.P. Morgan Healthcare Conference and an interview with Scrip, CEO Amy Burroughs laid out Terns’ plans for its allosteric BCR-ABL inhibitor in CML.

CMO Tahamtan Ahmadi explained Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.

CEO Christopher Viehbacher has said repeatedly that Biogen will build its pipeline internally and through deals, and Grogan reshuffled the research organization with that in mind.

CMO Tahamtan Ahmadi told Scrip that Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.

The J.P. Morgan Healthcare Conference and Biotech Showcase revealed what investors are really thinking about the health of the capital markets this year.

Scrip used the J.P. Morgan Healthcare Conference and Biotech Showcase to speak with investors and gauge the health of the capital markets this year.